Hoffmann-La Roche: Schizophrenia trials
The registry lists 19 Schizophrenia studies with Hoffmann-La Roche as lead sponsor. 0 are open to participants now and 3 have results posted.
Phase 1 5Phase 2 5Phase 3 6No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective DisorderCompletedNCT04512066Phase 2Results posted
- A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative SymptomsTerminatedNCT03669640Phase 2Results posted
- A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With AntipsychoticsCompletedNCT02953639Phase 2Results posted
- 18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With SchizophreniaCompletedNCT06880328Phase 1
- A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With AntipsychoticsCompletedNCT02824055Phase 1
- A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on RisperidoneCompletedNCT02019329Phase 1
- A Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia to Describe Medical Resource Utilization and Burden of IllnessCompletedNCT01959659
- A PET Study With RO5545965 in Healthy Male VolunteersCompletedNCT01923025Phase 1
- The Management of Schizophrenia in Clinical Practice (MOSAIC)CompletedNCT01746134
- An Non-Interventional Study of Patients With Persistent Symptoms of SchizophreniaCompletedNCT01634542
- A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)CompletedNCT01235585Phase 3
- A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)CompletedNCT01235559Phase 3
- A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)CompletedNCT01235520Phase 3
- A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of SchizophreniaCompletedNCT01234779Phase 2
- A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)CompletedNCT01192906Phase 3
- A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of SchizophreniaCompletedNCT01192880Phase 3
- A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)CompletedNCT01192867Phase 3
- A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective DisorderCompletedNCT01116830Phase 1
- A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.CompletedNCT00616798Phase 2